$NBTX News

Leerink Partners Maintains Outperform on Nanobiotix, Raises Price Target to $46

Nanobiotix Reports Q1 2026 Progress, Highlights 85.7% Response Rate In Phase 2 JNJ-1900 NSCLC Study, FDA Acceptance Of NANORAY-312 Protocol Amendment; Company Believes That The Net Proceeds From The Recent Follow-On Offering, Together With Its Cash And Cash Equivalents Of €42.1 Million As Of March 31, 2026

Nanobiotix Added to Euronext Tech Leaders Program and Index

Assessing Nanobiotix (ENXTPA:NANO) Valuation After Strong Recent Share Price Momentum

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

Nanobiotix Nanoprimer Pre-Treatment Demonstrates Reduced Hepatic Toxicity And Improved Systemic Bioavailability For LNP-DNA Cancer Immunotherapy In Preclinical Study

Voting Rights and Shares Capital of the Company

Nanobiotix S.A. 2025 Q4 - Results - Earnings Call Presentation

Guggenheim Maintains Buy on Nanobiotix, Raises Price Target to $36

Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript

Nanobiotix shares are trading higher after the company reported a year-over-year decrease in FY25 loss per share.

Nanobiotix shares are trading higher after the company reported a year-over-year decrease in FY25 loss per share.

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

UPDATE: Nanobiotix FY EPS $(0.58) Up From $(1.56) YoY, Sales $37.943M Miss $165.540M Estimate

Nanobiotix FY EPS $(0.58) Down From $1.56 YoY, Sales $37.943M Miss $165.540M Estimate

Nanobiotix's JNJ-1900 Demonstrates Acceptable Safety And 71.4% Overall Response Rate In First Phase 2 CONVERGE Data For Inoperable Stage 3 NSCLC

NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

NANOBIOTIX Statement Regarding Recent Media Speculation

Nanobiotix Issues Statement Regarding Recent Media Speculation Concerning Intentions For A Potential Public Takeover; Says There Is No Such Intention To Acquire Control Of The Company, And No Process Or Assessment Is Being Conducted Toward That End

Voting Rights and Shares Capital of the Company